Affiliation:
1. Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation;
First Moscow State Medical University, Ministry of Healthcare of the Russian Federation
2. Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare of the Russian Federation
Abstract
Overactive bladder (OAB) is a serious urination disorder which affects at least 17% of the population above 40 years old, of which 56% are women and 44% are men. M-cholinoblockers are the first line therapy and the main treatment for OAB. However, their side effects, along with low efficacy, force women to stop taking the drugs. Activation of beta-3-adrenergic receptors is known toreduce the tone of detrusor muscle in the bladder. This resulted in the invention of mirabegron (Mirabegron, Betmiga, Astellas Pharma Europe, Netherlands), the first drug of a new pharmacologic group (beta-3 adrenergic agonists) for the treatment of OAB. A selective beta-3 agonist, mirabegron has no side effects such as dry mouth, increased intraocular pressure or constipation. Numerous clinical studies demonstrated a reduction in the number of episodes of urinary incontinence and frequent urination in the mirabegron group compared to the placebo group.
Reference36 articles.
1. Abrams P. The standartisation of terminology of lower urinary tract function. Neurourol. and Urodyn, 2002, 21: 167-178.
2. Gadzhieva Zh.K. Narusheniya mocheispuskaniya: rukovodstvo. Pod red. Yu.G. Alyaeva. M.: GEOTAR-Media, 2010. 176 s.
3. Pushkar' D.Yu. Giperaktivnyi mochevoi puzyr' u zhenshchin. M.: MED press-inform, 2003. 160 s.
4. Dzhavad-Zade M.D., Derzhavin V.M., Vishnevskii E.L. Neirogennye disfunktsii mochevogo puzyrya. M.: Meditsina, 1989.
5. Milsom I, Abrams P, Cardozo L et al. How widespread are the symptoms of an overactive bladder and how are they managed? A populationbased prevalence study. BJU Int, 2001, 87: 760–6.